...
首页> 外文期刊>Drug Design, Development and Therapy >Kinase inhibitors: a new class of antirheumatic drugs
【24h】

Kinase inhibitors: a new class of antirheumatic drugs

机译:激酶抑制剂:一类新型的抗风湿药

获取原文
           

摘要

Abstract: The outlook for patients with rheumatoid arthritis has improved significantly over the last three decades with the use of disease-modifying antirheumatic drugs. However, despite the use of methotrexate, cytokine inhibitors, and molecules targeting T and B cells, a percentage of patients do not respond or lose their response over time. The autoimmune process in rheumatoid arthritis depends on activation of immune cells, which utilize intracellular kinases to respond to external stimuli such as cytokines, immune complexes, and antigens. In the past decade, small molecules targeting several kinases, such as p38 MAPK, Syk, and JAK have been developed. Several p38 MAPK inhibitors proved ineffective in treating rheumatoid arthritis. The Syk inhibitor, fostamatinib, proved superior to placebo in Phase II trials and is currently under Phase III investigation. Tofacitinib, a JAK1/3 inhibitor, was shown to be efficacious in two Phase III trials, while VX-509, a JAK3 inhibitor, showed promising results in a Phase II trial. Fostamatinib and tofacitinib were associated with increased rates of infection, elevation of liver enzymes, and neutropenia. Moreover, fostamatinib caused elevations of blood pressure and diarrhea, while tofacitinib was associated with an increase in creatinine and elevation of lipid levels.
机译:摘要:在过去的三十年中,通过使用抗病风湿药物,类风湿关节炎患者的前景有了显着改善。但是,尽管使用了甲氨蝶呤,细胞因子抑制剂以及靶向T细胞和B细胞的分子,但仍有一定比例的患者随着时间的推移没有反应或失去反应。类风湿性关节炎的自身免疫过程取决于免疫细胞的活化,免疫细胞利用细胞内激酶对诸如细胞因子,免疫复合物和抗原之类的外部刺激作出反应。在过去的十年中,已经开发出了针对几种激酶的小分子,例如p38 MAPK,Syk和JAK。几种p38 MAPK抑制剂被证明对类风湿关节炎无效。 Syk抑制剂fostamatinib在II期试验中被证明优于安慰剂,目前正在进行III期研究。 JAK1 / 3抑制剂托法替尼在两项III期临床试验中均显示有效,而JAK3抑制剂VX-509在II期临床试验中显示出可喜的结果。 Fostamatinib和tofacitinib与感染率增加,肝酶升高和中性粒细胞减少有关。此外,福司他替尼引起血压升高和腹泻,而托法替尼与肌酐升高和血脂水平升高相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号